FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898861008> ?p ?o ?g. }

• W2898861008 abstract "Objective: To examine amantadine’s effect on the progression of PSP. Background: A number of small case series report benefits of amantadine in PSP but results are not dramatic or consistent. To explore if amantadine could be beneficial in slowing disease progression we looked at a convenience sample from a study of davunetide in PSP. Design/Methods: This is a supplementary analysis using data from a study that did not show benefit with 52 weeks of davunetide treatment on PSP symptom progression. 55 of 313 randomized participants were on amantadine. We examined the change in outcome measures over the course of the study in those on and not on amantadine. The primary outcome measures were the PSP rating scale (PSPRS) and Schwab and England Activities of daily living (SEADL). We corrected for baseline PSPRS ( 40), coenzyme Q10 (yes or no), and age ( 70); which were used for randomization in the initial study. Results: Before any corrections subjects on amantadine saw a significant one year reduction in SEADL score of 12.5 point compared to 17.6 points(t=−2.02, p=0.046) in the other subjects. There was also a non-significant difference in the PSPRS score with a change of 9.6 points in the amantadine group versus 11.3 points in non-amantadine subjects (t=1.18, p=0.24). When correcting for age, baseline PSPRS, and coenzyme Q10 use the only significant difference between groups was more improved performance in a secondary outcome measure, phonetic fluency (p=0.042), in the amantadine group. With corrections the p value became non-significant at 0.091 for the SEADL data. Conclusions: Amantadine may show beneficial effects with respect to quality of life. Less clear is if amantadine has an effect on progression of PSP symptoms. There are clear limitations of this data, but a randomized trial directly assessing amantadine in PSP may be justified. Study Supported by: Data is from the Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy performed by the AL-108-231 investigators. Disclosure: Dr. Hiller has nothing to disclose. Dr. Murchison has nothing to disclose. Dr. Nichols has nothing to disclose. Dr. Quinn has nothing to disclose." @default.
• W2898861008 created "2018-11-09" @default.
• W2898861008 creator A5008565592 @default.
• W2898861008 creator A5062790117 @default.
• W2898861008 creator A5067762225 @default.
• W2898861008 creator A5075093941 @default.
• W2898861008 date "2018-04-10" @default.
• W2898861008 modified "2023-09-24" @default.
• W2898861008 title "The Effects of Amantadine on the Progression of Progressive Supranuclear Palsy (PSP) (P6.068)" @default.
• W2898861008 hasPublicationYear "2018" @default.
• W2898861008 type Work @default.
• W2898861008 sameAs 2898861008 @default.
• W2898861008 citedByCount "0" @default.
• W2898861008 crossrefType "journal-article" @default.
• W2898861008 hasAuthorship W2898861008A5008565592 @default.
• W2898861008 hasAuthorship W2898861008A5062790117 @default.
• W2898861008 hasAuthorship W2898861008A5067762225 @default.
• W2898861008 hasAuthorship W2898861008A5075093941 @default.
• W2898861008 hasConcept C126322002 @default.
• W2898861008 hasConcept C15744967 @default.
• W2898861008 hasConcept C168563851 @default.
• W2898861008 hasConcept C204243189 @default.
• W2898861008 hasConcept C2777374534 @default.
• W2898861008 hasConcept C2779384338 @default.
• W2898861008 hasConcept C535046627 @default.
• W2898861008 hasConcept C71924100 @default.
• W2898861008 hasConcept C98274493 @default.
• W2898861008 hasConceptScore W2898861008C126322002 @default.
• W2898861008 hasConceptScore W2898861008C15744967 @default.
• W2898861008 hasConceptScore W2898861008C168563851 @default.
• W2898861008 hasConceptScore W2898861008C204243189 @default.
• W2898861008 hasConceptScore W2898861008C2777374534 @default.
• W2898861008 hasConceptScore W2898861008C2779384338 @default.
• W2898861008 hasConceptScore W2898861008C535046627 @default.
• W2898861008 hasConceptScore W2898861008C71924100 @default.
• W2898861008 hasConceptScore W2898861008C98274493 @default.
• W2898861008 hasLocation W28988610081 @default.
• W2898861008 hasOpenAccess W2898861008 @default.
• W2898861008 hasPrimaryLocation W28988610081 @default.
• W2898861008 hasRelatedWork W1702894073 @default.
• W2898861008 hasRelatedWork W1726357000 @default.
• W2898861008 hasRelatedWork W1980776506 @default.
• W2898861008 hasRelatedWork W2051786301 @default.
• W2898861008 hasRelatedWork W2132170828 @default.
• W2898861008 hasRelatedWork W2241078523 @default.
• W2898861008 hasRelatedWork W2256753007 @default.
• W2898861008 hasRelatedWork W2323283016 @default.
• W2898861008 hasRelatedWork W2337797571 @default.
• W2898861008 hasRelatedWork W2402539097 @default.
• W2898861008 hasRelatedWork W2534311425 @default.
• W2898861008 hasRelatedWork W2553477592 @default.
• W2898861008 hasRelatedWork W2560841097 @default.
• W2898861008 hasRelatedWork W2804862081 @default.
• W2898861008 hasRelatedWork W2895399430 @default.
• W2898861008 hasRelatedWork W2993085210 @default.
• W2898861008 hasRelatedWork W2993453317 @default.
• W2898861008 hasRelatedWork W3138466359 @default.
• W2898861008 hasRelatedWork W3144215795 @default.
• W2898861008 hasRelatedWork W2181605705 @default.
• W2898861008 hasVolume "90" @default.
• W2898861008 isParatext "false" @default.
• W2898861008 isRetracted "false" @default.
• W2898861008 magId "2898861008" @default.
• W2898861008 workType "article" @default.